Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs

Bibliography

• JCiccolini, CMercier, LDahan, NAndré. Integrating pharmacogenetics into gemcitabine dosing–time for a change? Nat Rev Clin Oncol 2011;8(7):439–44
   PubMed Web of Science ®Google Scholar
• HCKirch, JSchröder, HHoppe, et al. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998;26(5):421–5
   PubMed Web of Science ®Google Scholar
• LYue, YSaikawa, KOta, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003;13(1):29–38
   PubMedGoogle Scholar
• JCiccolini, AEvrard, LM’Batchi, et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 2012;13(4):393–7
   PubMed Web of Science ®Google Scholar
• DMicozzi, FMCarpi, SPucciarelli, et al. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol 2014;63:64–74
   PubMed Web of Science ®Google Scholar
• JKSchröder, CKirch, SSeeber, JSchütte. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998;103(4):1096–103
   PubMed Web of Science ®Google Scholar
• YSTeng, JEAnderson, ERGiblett. Cytidine deaminase: a new genetic polymorphism demonstrated in human granulocytes. Am J Hum Genet 1975;27(4):492–7
   PubMed Web of Science ®Google Scholar
• SMFitzgerald, RKGoyal, WROsborne, et al. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 2006;119(3):276–83
   PubMed Web of Science ®Google Scholar
• JAGilbert, OESalavaggione, YJi, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12(6):1794–803
   PubMed Web of Science ®Google Scholar
• EGiovannetti, ACLaan, EVasile, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008;27(6):720–5
   PubMed Web of Science ®Google Scholar
• VLudovini, IFloriani, LPistola, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 2011;6(12):2018–26
   PubMed Web of Science ®Google Scholar
• JGMaring, FMWachters, MSlijfer, et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010;66(6):611–17
   PubMed Web of Science ®Google Scholar
• CMercier, CDupuis, ABlesius, et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol 2009;63(6):1177–80
   PubMed Web of Science ®Google Scholar
• SParmar, ASeeringer, DDenich, et al. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics 2011;12(4):503–14
   PubMed Web of Science ®Google Scholar
• UMahlknecht, CLDransfeld, NBulut, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009;23(10):1929–32
   PubMed Web of Science ®Google Scholar
• CRaynal, JCiccolini, CMercier, et al. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. Ther Drug Monit 2010;32(1):53–60
   PubMed Web of Science ®Google Scholar
• RASoo, LZWang, SSNg, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009;63(1):121–7
   PubMed Web of Science ®Google Scholar
• ESugiyama, NKaniwa, SRKim, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007;25(1):32–42
   PubMed Web of Science ®Google Scholar
• CMercier, AEvrard, JCiccolini. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. J Clin Oncol 2007;25(30):4855; author reply 4855-6
   PubMed Web of Science ®Google Scholar
• JCiccolini, LDahan, NAndré, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010;28(1):160–5
   PubMed Web of Science ®Google Scholar
• EGiovannetti, CTibaldi, AFalcone, et al. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. J Clin Oncol 2010;28(14):e221–2; author reply e223-5
   PubMed Web of Science ®Google Scholar
• GJPeters, RJHoneywell, MMaulandi, et al. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids 2014;33(4-6):403–12
   PubMed Web of Science ®Google Scholar
• CTibaldi, EGiovannetti, MTiseo, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 2012;23(3):670–7
   PubMed Web of Science ®Google Scholar
• ESugiyama, NKaniwa, SRKim, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet 2010;49(8):549–58
   PubMed Web of Science ®Google Scholar
• DCaronia, MMartin, JSastre, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011;17(7):2006–13
   PubMed Web of Science ®Google Scholar
• CMercier, CRaynal, LDahan, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007;17(10):841–4
   PubMed Web of Science ®Google Scholar
• CSerdjebi, JCiccolini, FFina, et al. Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift? Pharmacogenet Genomics 2014;24(10):527–9
   PubMed Web of Science ®Google Scholar
• HUeno, NKaniwa, TOkusaka, et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009;100(6):870–3
   PubMed Web of Science ®Google Scholar
• CTibaldi, EGiovannetti, EVasile, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14(6):1797–803
   PubMed Web of Science ®Google Scholar
• AAbraham, SVaratharajan, SAbbas, et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 2012;13(3):269–82
   PubMed Web of Science ®Google Scholar
• JXu, YZhou, JZhang, et al. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clin Chim Acta 2012;413(15-16):1284–7
   PubMed Web of Science ®Google Scholar
• JABaker, ERWickremsinhe, CHLi, et al. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos 2013;41(3):541–5
   PubMed Web of Science ®Google Scholar
• RZMahfouz, AJankowska, QEbrahem, et al. Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res 2013;19(4):938–48
   PubMed Web of Science ®Google Scholar
• RGrepin, MGuyot, MJacquin, et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene 2012;31(13):1683–94
   PubMed Web of Science ®Google Scholar
• TDe Pas, Fde Braud, RDanesi, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2000;11(7):821–7
   PubMed Web of Science ®Google Scholar
• KYonemori, HUeno, TOkusaka, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005;11(7):2620–4
   PubMed Web of Science ®Google Scholar
• JCiccolini, AEvrard, BLacarelle. A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome–letter. Clin Cancer Res 2012;18(1):317
   PubMed Web of Science ®Google Scholar
• ESugiyama, SJLee, SSLee, et al. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet 2009;24(6):553–6
   PubMed Web of Science ®Google Scholar
• DAYardley. Gemcitabine and taxanes as a new standard of care in breast cancer. Clin Breast Cancer 2004;4(Suppl 3):S107–12
   Google Scholar
• ASandler, DSEttinger. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999;4(3):241–51
   PubMedGoogle Scholar
• MDShelley, GJones, ACleves, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 2012;109(4):496–505
   PubMed Web of Science ®Google Scholar
• JRKroep, GGiaccone, CTolis, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 2000;83(8):1069–76
   PubMed Web of Science ®Google Scholar
• TMKim, SKim, YOAhn, et al. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. Leuk Lymphoma 2014;55(4):940–3
   PubMed Web of Science ®Google Scholar
• EMini, SNobili, BCaciagli, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17(Suppl 5):v7–12
   PubMed Web of Science ®Google Scholar
• CSerdjebi, JFSeitz, JCiccolini, et al. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics 2013;14(9):1047–51
   PubMed Web of Science ®Google Scholar
• JJFarrell, KBae, JWong, et al. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 2012;12(5):395–403
   PubMed Web of Science ®Google Scholar
• GMKeating. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2012;72(8):1111–36
   PubMed Web of Science ®Google Scholar
• MJoerger, SABurgers, PBaas, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012;118(9):2466–75
   PubMed Web of Science ®Google Scholar
• JCiccolini, GJPeters, EGiovannetti. Gender, cytidine deaminase, and 5-aza/decitabine–letter. Clin Cancer Res 2013;19(11):3105
   PubMed Web of Science ®Google Scholar
• RFanciullino, CSerdjebi, SMollard, et al. Abstract 2208: cytidine deaminase deficiency and severe toxicities upon azacytidine intake: clinical observations and experimental evidences. Proceedings: AACR 104th Annual Meeting 2013; 6 – 10 April 2013; Washington, DC. Cancer Res 2013;73(8):abstract nr 2208
   Google Scholar
• IJFalk, AFyrberg, EPaul, et al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5’-nucleotidase. Am J Hematol 2013;88(12):1001–6
   PubMed Web of Science ®Google Scholar
• PPXu, BAChen, JFFeng, et al. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Chin Med J (Engl) 2012;125(12):2137–43
   PubMed Web of Science ®Google Scholar
• JSchüller, JCassidy, EDumont, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291–7
   PubMed Web of Science ®Google Scholar
• MMiwa, MUra, MNishida, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34(8):1274–81
   PubMed Web of Science ®Google Scholar
• TMorita, AMatsuzaki, SKurokawa, ATokue. Forced expression of cytidine deaminase confers sensitivity to capecitabine. Oncology 2003;65(3):267–74
   PubMed Web of Science ®Google Scholar
• LDahan, JCiccolini, AEvrard, et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. J Clin Oncol 2012;30(4):e41–4
   PubMed Web of Science ®Google Scholar
• FAndré, JCiccolini, JPSpano, et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics 2013;14(8):931–9
   PubMed Web of Science ®Google Scholar
• CMercier, LDahan, LOuafik, et al. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010;66(9):959–60
   PubMed Web of Science ®Google Scholar